Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

Immune checkpoint inhibitors are immune stimulatory drugs used to treat many types of cancer. These drugs are antibodies against inhibitory proteins, such as CTLA-4 and PD-1/PD-L1, that are expressed on immune cells. When bound, they allow for increased stimulation of T cells to fight tumor cells. H...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2021-10, Vol.13 (20), p.5218
Hauptverfasser: Shalata, Walid, Abu-Salman, Amjad, Steckbeck, Rachel, Mathew Jacob, Binil, Massalha, Ismaell, Yakobson, Alexander
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 20
container_start_page 5218
container_title Cancers
container_volume 13
creator Shalata, Walid
Abu-Salman, Amjad
Steckbeck, Rachel
Mathew Jacob, Binil
Massalha, Ismaell
Yakobson, Alexander
description Immune checkpoint inhibitors are immune stimulatory drugs used to treat many types of cancer. These drugs are antibodies against inhibitory proteins, such as CTLA-4 and PD-1/PD-L1, that are expressed on immune cells. When bound, they allow for increased stimulation of T cells to fight tumor cells. However, immune checkpoint inhibitors have several immune-related adverse effects. Many cases have come to light recently of cardiotoxicity as a result of treatment with these drugs. Cardiotoxicity from immune checkpoint inhibitors is unique due to its rarity and high mortality rate. Patients with this toxicity may present with myocarditis, pericarditis, Takotsubo cardiomyopathy, conduction disorders, and others within just a few weeks of starting immune checkpoint inhibitors. We present here a review of the current research on immune checkpoint inhibitors, their associated cardiotoxicities, the timing of presentation of these conditions, lab tests and histology for each condition, and finally the treatment of patients with cardiotoxicity. We observe a positive skew in the onset of presentation, which is significant for the treating physician.
doi_str_mv 10.3390/cancers13205218
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8534225</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584352138</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-9d6f5cf587dc2c48f90b9ec811ad9d57b6dcddb98241ad1141812dcdeb81ad9b3</originalsourceid><addsrcrecordid>eNpdkd1LwzAUxYMobqjPvknAF1-qzUfb1AdhFD8GgjDnc0iT1EbXZibp5v57q5tDd19yOfnlcG8OAKcoviQkj6-kaKV2HhEcJxixPTDEcYajNM3p_p9-AE68f4v7IgRlaXYIBoSmLCZpMgSTQjhlhIRT-2mkCSs48t5KI4JWcGlCDcdN07UaFrWW73Nr2gDHbW1KE6zz13AEn1c-6EYEI-FEL4xeHoODSsy8PtmcR-Dl7nZaPESPT_fjYvQYSZpmIcpVWiWySlimJJaUVXlc5loyhITKVZKVqZJKlTnDtFcQoogh3Eu6ZN9ESY7Azdp33pWNVlK3wYkZnzvTCLfiVhj-_6Y1NX-1C84SQjFOeoOLjYGzH532gTfGSz2biVbbznOcMJrlFBHWo-c76JvtXNuv90OR_v9_qKs1JZ313ulqOwyK-XdkfCey_sXZ3x22_G9A5Av9cZTK</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2584352138</pqid></control><display><type>article</type><title>Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Shalata, Walid ; Abu-Salman, Amjad ; Steckbeck, Rachel ; Mathew Jacob, Binil ; Massalha, Ismaell ; Yakobson, Alexander</creator><creatorcontrib>Shalata, Walid ; Abu-Salman, Amjad ; Steckbeck, Rachel ; Mathew Jacob, Binil ; Massalha, Ismaell ; Yakobson, Alexander</creatorcontrib><description>Immune checkpoint inhibitors are immune stimulatory drugs used to treat many types of cancer. These drugs are antibodies against inhibitory proteins, such as CTLA-4 and PD-1/PD-L1, that are expressed on immune cells. When bound, they allow for increased stimulation of T cells to fight tumor cells. However, immune checkpoint inhibitors have several immune-related adverse effects. Many cases have come to light recently of cardiotoxicity as a result of treatment with these drugs. Cardiotoxicity from immune checkpoint inhibitors is unique due to its rarity and high mortality rate. Patients with this toxicity may present with myocarditis, pericarditis, Takotsubo cardiomyopathy, conduction disorders, and others within just a few weeks of starting immune checkpoint inhibitors. We present here a review of the current research on immune checkpoint inhibitors, their associated cardiotoxicities, the timing of presentation of these conditions, lab tests and histology for each condition, and finally the treatment of patients with cardiotoxicity. We observe a positive skew in the onset of presentation, which is significant for the treating physician.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13205218</identifier><identifier>PMID: 34680365</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Antidotes ; Antigens ; Cancer ; Cancer therapies ; Cardiomyocytes ; Cardiomyopathy ; Cardiotoxicity ; Cell cycle ; Cell death ; COVID-19 ; CTLA-4 protein ; Cytotoxicity ; Heart diseases ; Heart failure ; Immune checkpoint inhibitors ; Immune system ; Immunosuppressive agents ; Inflammation ; Ischemia ; Lymphocytes ; Lymphocytes T ; Myocarditis ; Patients ; PD-1 protein ; PD-L1 protein ; Pericarditis ; Smooth muscle ; Systematic Review ; Tumor cells ; Tumors</subject><ispartof>Cancers, 2021-10, Vol.13 (20), p.5218</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-9d6f5cf587dc2c48f90b9ec811ad9d57b6dcddb98241ad1141812dcdeb81ad9b3</citedby><cites>FETCH-LOGICAL-c467t-9d6f5cf587dc2c48f90b9ec811ad9d57b6dcddb98241ad1141812dcdeb81ad9b3</cites><orcidid>0000-0001-7715-1825 ; 0000-0003-3127-4293 ; 0000-0003-2319-4445 ; 0000-0002-7570-4550</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534225/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534225/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34680365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shalata, Walid</creatorcontrib><creatorcontrib>Abu-Salman, Amjad</creatorcontrib><creatorcontrib>Steckbeck, Rachel</creatorcontrib><creatorcontrib>Mathew Jacob, Binil</creatorcontrib><creatorcontrib>Massalha, Ismaell</creatorcontrib><creatorcontrib>Yakobson, Alexander</creatorcontrib><title>Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Immune checkpoint inhibitors are immune stimulatory drugs used to treat many types of cancer. These drugs are antibodies against inhibitory proteins, such as CTLA-4 and PD-1/PD-L1, that are expressed on immune cells. When bound, they allow for increased stimulation of T cells to fight tumor cells. However, immune checkpoint inhibitors have several immune-related adverse effects. Many cases have come to light recently of cardiotoxicity as a result of treatment with these drugs. Cardiotoxicity from immune checkpoint inhibitors is unique due to its rarity and high mortality rate. Patients with this toxicity may present with myocarditis, pericarditis, Takotsubo cardiomyopathy, conduction disorders, and others within just a few weeks of starting immune checkpoint inhibitors. We present here a review of the current research on immune checkpoint inhibitors, their associated cardiotoxicities, the timing of presentation of these conditions, lab tests and histology for each condition, and finally the treatment of patients with cardiotoxicity. We observe a positive skew in the onset of presentation, which is significant for the treating physician.</description><subject>Antibodies</subject><subject>Antidotes</subject><subject>Antigens</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cardiomyocytes</subject><subject>Cardiomyopathy</subject><subject>Cardiotoxicity</subject><subject>Cell cycle</subject><subject>Cell death</subject><subject>COVID-19</subject><subject>CTLA-4 protein</subject><subject>Cytotoxicity</subject><subject>Heart diseases</subject><subject>Heart failure</subject><subject>Immune checkpoint inhibitors</subject><subject>Immune system</subject><subject>Immunosuppressive agents</subject><subject>Inflammation</subject><subject>Ischemia</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Myocarditis</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Pericarditis</subject><subject>Smooth muscle</subject><subject>Systematic Review</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkd1LwzAUxYMobqjPvknAF1-qzUfb1AdhFD8GgjDnc0iT1EbXZibp5v57q5tDd19yOfnlcG8OAKcoviQkj6-kaKV2HhEcJxixPTDEcYajNM3p_p9-AE68f4v7IgRlaXYIBoSmLCZpMgSTQjhlhIRT-2mkCSs48t5KI4JWcGlCDcdN07UaFrWW73Nr2gDHbW1KE6zz13AEn1c-6EYEI-FEL4xeHoODSsy8PtmcR-Dl7nZaPESPT_fjYvQYSZpmIcpVWiWySlimJJaUVXlc5loyhITKVZKVqZJKlTnDtFcQoogh3Eu6ZN9ESY7Azdp33pWNVlK3wYkZnzvTCLfiVhj-_6Y1NX-1C84SQjFOeoOLjYGzH532gTfGSz2biVbbznOcMJrlFBHWo-c76JvtXNuv90OR_v9_qKs1JZ313ulqOwyK-XdkfCey_sXZ3x22_G9A5Av9cZTK</recordid><startdate>20211018</startdate><enddate>20211018</enddate><creator>Shalata, Walid</creator><creator>Abu-Salman, Amjad</creator><creator>Steckbeck, Rachel</creator><creator>Mathew Jacob, Binil</creator><creator>Massalha, Ismaell</creator><creator>Yakobson, Alexander</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7715-1825</orcidid><orcidid>https://orcid.org/0000-0003-3127-4293</orcidid><orcidid>https://orcid.org/0000-0003-2319-4445</orcidid><orcidid>https://orcid.org/0000-0002-7570-4550</orcidid></search><sort><creationdate>20211018</creationdate><title>Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review</title><author>Shalata, Walid ; Abu-Salman, Amjad ; Steckbeck, Rachel ; Mathew Jacob, Binil ; Massalha, Ismaell ; Yakobson, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-9d6f5cf587dc2c48f90b9ec811ad9d57b6dcddb98241ad1141812dcdeb81ad9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Antidotes</topic><topic>Antigens</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cardiomyocytes</topic><topic>Cardiomyopathy</topic><topic>Cardiotoxicity</topic><topic>Cell cycle</topic><topic>Cell death</topic><topic>COVID-19</topic><topic>CTLA-4 protein</topic><topic>Cytotoxicity</topic><topic>Heart diseases</topic><topic>Heart failure</topic><topic>Immune checkpoint inhibitors</topic><topic>Immune system</topic><topic>Immunosuppressive agents</topic><topic>Inflammation</topic><topic>Ischemia</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Myocarditis</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Pericarditis</topic><topic>Smooth muscle</topic><topic>Systematic Review</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shalata, Walid</creatorcontrib><creatorcontrib>Abu-Salman, Amjad</creatorcontrib><creatorcontrib>Steckbeck, Rachel</creatorcontrib><creatorcontrib>Mathew Jacob, Binil</creatorcontrib><creatorcontrib>Massalha, Ismaell</creatorcontrib><creatorcontrib>Yakobson, Alexander</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shalata, Walid</au><au>Abu-Salman, Amjad</au><au>Steckbeck, Rachel</au><au>Mathew Jacob, Binil</au><au>Massalha, Ismaell</au><au>Yakobson, Alexander</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2021-10-18</date><risdate>2021</risdate><volume>13</volume><issue>20</issue><spage>5218</spage><pages>5218-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Immune checkpoint inhibitors are immune stimulatory drugs used to treat many types of cancer. These drugs are antibodies against inhibitory proteins, such as CTLA-4 and PD-1/PD-L1, that are expressed on immune cells. When bound, they allow for increased stimulation of T cells to fight tumor cells. However, immune checkpoint inhibitors have several immune-related adverse effects. Many cases have come to light recently of cardiotoxicity as a result of treatment with these drugs. Cardiotoxicity from immune checkpoint inhibitors is unique due to its rarity and high mortality rate. Patients with this toxicity may present with myocarditis, pericarditis, Takotsubo cardiomyopathy, conduction disorders, and others within just a few weeks of starting immune checkpoint inhibitors. We present here a review of the current research on immune checkpoint inhibitors, their associated cardiotoxicities, the timing of presentation of these conditions, lab tests and histology for each condition, and finally the treatment of patients with cardiotoxicity. We observe a positive skew in the onset of presentation, which is significant for the treating physician.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34680365</pmid><doi>10.3390/cancers13205218</doi><orcidid>https://orcid.org/0000-0001-7715-1825</orcidid><orcidid>https://orcid.org/0000-0003-3127-4293</orcidid><orcidid>https://orcid.org/0000-0003-2319-4445</orcidid><orcidid>https://orcid.org/0000-0002-7570-4550</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2021-10, Vol.13 (20), p.5218
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8534225
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central
subjects Antibodies
Antidotes
Antigens
Cancer
Cancer therapies
Cardiomyocytes
Cardiomyopathy
Cardiotoxicity
Cell cycle
Cell death
COVID-19
CTLA-4 protein
Cytotoxicity
Heart diseases
Heart failure
Immune checkpoint inhibitors
Immune system
Immunosuppressive agents
Inflammation
Ischemia
Lymphocytes
Lymphocytes T
Myocarditis
Patients
PD-1 protein
PD-L1 protein
Pericarditis
Smooth muscle
Systematic Review
Tumor cells
Tumors
title Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A23%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiac%20Toxicity%20Associated%20with%20Immune%20Checkpoint%20Inhibitors:%20A%20Systematic%20Review&rft.jtitle=Cancers&rft.au=Shalata,%20Walid&rft.date=2021-10-18&rft.volume=13&rft.issue=20&rft.spage=5218&rft.pages=5218-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13205218&rft_dat=%3Cproquest_pubme%3E2584352138%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2584352138&rft_id=info:pmid/34680365&rfr_iscdi=true